Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 5/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111356 | 0.85 | FEN1 (0.38) | — | |
| SCHEMBL20111693 | 0.85 | ALOX5AP (0.39) | — | |
| SCHEMBL20111290 | 0.84 | PTGDR2 (0.37) | — | |
| SCHEMBL20102395 | 0.80 | MEN1 (0.33) | FPR2PTGS1PTGS2 | |
| SCHEMBL20111432 | 0.79 | FPR2 (0.31) | FPR2 | |
| SCHEMBL20102509 | 0.79 | — | — | |
| SCHEMBL20111340 | 0.78 | — | — | |
| SCHEMBL20117669 | 0.78 | SCN9A (0.43) | — | |
| SCHEMBL20102452 | 0.78 | KDM1A (0.34) | KDM1AFPR2PIM1PIM3PIM2 | |
| SCHEMBL20111306 | 0.77 | SCN9A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3315583-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC Corporation (JP) | 2018-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | KDM1A 1263/4885ACHE 2673/4885FPR2 869/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | KDM1A 1263/4885ACHE 2673/4885FPR2 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.